Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s11239-021-02504-5 http://scihub22266oqcxt.onion/10.1007/s11239-021-02504-5 34146235!8214061!34146235     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=34146235&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       J+Thromb+Thrombolysis 2021 ; 52 (4): 1032-1035 Nephropedia Template TP {{tp|p=34146235|t=2021. External validation of the IMPROVE-DD risk assessment model for venous thromboembolism among inpatients with COVID-19 |pdf=|usr=}}{{34146235}} gab.com Text External validation of the IMPROVE-DD risk assessment model for venous thromboembolism among inpatients with COVID-19 JO: J Thromb Thrombolysis http://www.kidney.de/pget.php?&tw=1&pmid=34146235 #FOAvip There is a need to discriminate which COVID-19 inpatients are at higher risk for venous thromboembolism (VTE) to inform prophylaxis strategies. The IMPROVE-DD VTE risk assessment model (RAM) has previously demonstrated good discrimination in non-COVID populations. We aimed to externally validate the IMPROVE-DD VTE RAM in medical patients hospitalized with COVID-19. This retrospective cohort study evaluated the IMPROVE-DD VTE RAM in adult patients with COVID-19 admitted to one of thirteen Northwell Health hospitals in the New York metropolitan area between March 1, 2020 and April 27, 2020. VTE was defined as new-onset symptomatic deep venous thrombosis or pulmonary embolism. To assess the predictive value of the RAM, the receiver operating characteristic (ROC) curve was plotted and the area under the curve (AUC) was calculated. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated. Of 9407 patients who met study criteria, 274 patients developed VTE with a prevalence of 2.91%. The VTE rate was 0.41% for IMPROVE-DD score 0-1 (low risk), 1.21% for score 2-3 (moderate risk), and 5.30% for score >/= 4 (high risk). Approximately 45.7% of patients were classified as high VTE risk, 33.3% moderate risk, and 21.0% low risk. Discrimination of low versus moderate-high VTE risk demonstrated sensitivity 0.971, specificity 0.215, PPV 0.036, and NPV 0.996. ROC AUC was 0.703. In this external validation study, the IMPROVE-DD VTE RAM demonstrated very good discrimination to identify hospitalized COVID-19 patients at low, moderate, and high VTE risk. Twit Text FOAVip External validation of the IMPROVE-DD risk assessment model for venous thromboembolism among inpatients with COVID-19 ????J Thromb Thrombolysis http://www.kidney.de/pget.php?&tw=1&pmid=34146235 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34146235 #FOAvip English Wikipedia <ref>{{Cite pmid|34146235}}</ref> External validation of the IMPROVE-DD risk assessment model for venous thromboembolism among inpatients with COVID-19 #MMPMID34146235 Goldin M; Lin SK; Kohn N; Qiu M; Cohen SL; Barish MA; Gianos E; Diaz A; Richardson S; Giannis D; Chatterjee S; Coppa K; Hirsch JS; Ngu S; Firoozan S; McGinn T; Spyropoulos AC J Thromb Thrombolysis 2021[Nov]; 52 (4): 1032-1035 PMID34146235show ga There is a need to discriminate which COVID-19 inpatients are at higher risk for venous thromboembolism (VTE) to inform prophylaxis strategies. The IMPROVE-DD VTE risk assessment model (RAM) has previously demonstrated good discrimination in non-COVID populations. We aimed to externally validate the IMPROVE-DD VTE RAM in medical patients hospitalized with COVID-19. This retrospective cohort study evaluated the IMPROVE-DD VTE RAM in adult patients with COVID-19 admitted to one of thirteen Northwell Health hospitals in the New York metropolitan area between March 1, 2020 and April 27, 2020. VTE was defined as new-onset symptomatic deep venous thrombosis or pulmonary embolism. To assess the predictive value of the RAM, the receiver operating characteristic (ROC) curve was plotted and the area under the curve (AUC) was calculated. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated. Of 9407 patients who met study criteria, 274 patients developed VTE with a prevalence of 2.91%. The VTE rate was 0.41% for IMPROVE-DD score 0-1 (low risk), 1.21% for score 2-3 (moderate risk), and 5.30% for score >/= 4 (high risk). Approximately 45.7% of patients were classified as high VTE risk, 33.3% moderate risk, and 21.0% low risk. Discrimination of low versus moderate-high VTE risk demonstrated sensitivity 0.971, specificity 0.215, PPV 0.036, and NPV 0.996. ROC AUC was 0.703. In this external validation study, the IMPROVE-DD VTE RAM demonstrated very good discrimination to identify hospitalized COVID-19 patients at low, moderate, and high VTE risk. |*COVID-19/complications[MESH] |*Risk Assessment[MESH] |*Venous Thromboembolism/diagnosis/epidemiology[MESH] |Humans[MESH] |Inpatients[MESH] |New York City[MESH] |Retrospective Studies[MESH]External validation of the IMPROVE-DD risk assessment model for venous(epmc).pdf DeepDyve Pubget Overpricing